October 20, 2025

Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development Progress

CLARAMETYX BIOSCIENCES STRENGTHENS LEADERSHIP TEAM TO ACCELERATE PIPELINE AND CORPORATE DEVELOPMENT PROGRESS

Steve St. Onge, PharmD, MBA promoted to Chief Business Officer

Brendan Doran, PharmD, appointed Senior Vice President of Clinical Development

COLUMBUS, Ohio – October 20, 2025 – Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory disease, today announced the promotion of Steve St. Onge, PharmD, MBA to Chief Business Officer, and the hiring of Brendan Doran, PharmD, as Senior Vice President of Clinical Development. These leadership additions position the company to accelerate progress as its pipeline rapidly advances toward later stage clinical development.

“Strengthening our bench of seasoned executives is critical to achieving our near-term goals, specifically in accelerating progress in our pipeline programs as well as advancing corporate development and financing efforts,” said David V. Richards, Chief Executive Officer, Clarametyx. “Steve has been a tremendous asset to the team and we believe this expanded role will enable him to execute important strategic priorities for the company. We also welcome Brendan, who brings a long track record of success in rigorously advancing clinical development activities and will play a key role in supporting the next stage of studies for our therapeutic and vaccine programs.”

Dr. St. Onge has served as Senior Vice President of Corporate Development for Clarametyx since April 2024. He joined the team from Paratek Pharmaceuticals, where he led business development, licensing and corporate communications and played a pivotal role in achieving multiple corporate milestones, including the successful commercialization of NUZYRA® and the company’s $462 million take-private acquisition in 2023. Earlier in his career, he held roles in medical affairs and clinical research at Paratek, Tardis, and The Medicines Company.  He earned a Doctor of Pharmacy degree from the Albany College of Pharmacy and an MBA from Endicott College.

Dr. Doran joins Clarametyx with more than 15 years of experience leading cross-functional teams to advance novel therapies across a wide range of therapeutic areas including infectious disease, immunology, and rare diseases. He was most recently Head of Clinical Operations at CinRx Pharma, and previously served in leadership roles at CTI Clinical Trial and Consulting Services. In addition to his industry experience, he has practiced as a clinical pharmacist in a hospital setting and maintains an academic appointment at the University of Cincinnati. He earned a Bachelor of Science in Biology from Mercyhurst University and a Doctor of Pharmacy degree from the Lake Erie College of Osteopathic Medicine School of Pharmacy.

About CMTX-101
CMTX-101 is an investigational, immune-enabling antibody therapy for chronic respiratory diseases. The therapy is designed to rapidly destroy the pro-inflammatory structure of bacterial biofilms to undermine extracellular bacterial defenses and enable more effective immune and antibiotic intervention. Because the target is universally present across bacterial biofilms, the approach can be employed to treat a wide range of biofilm-driven respiratory infections, with the goal of dramatically reducing inflammation and preventing progressive lung function decline. CMTX-101 is currently in a Phase 2 study in cystic fibrosis, with opportunities to expand to other chronic respiratory diseases including nontuberculous mycobacterial (NTM) lung disease, non-CF bronchiectasis, and chronic obstructive pulmonary disease (COPD).

About Clarametyx Biosciences
Clarametyx Biosciences is combating the formidable challenge of chronic respiratory diseases through an innovative technology platform targeting the biofilm—a protective layer around bacteria that drives inflammation and disease exacerbation. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines, including CMTX-101, which is in a Phase 2 study for cystic fibrosis-related, biofilm-driven infections, and CMTX-301, which is in preclinical development. For more information, visit us on the web or on LinkedIn.

Media Contact:
Kellie Hotz
khotz@clarametyx.com
# # #

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.